Pediatric bone sarcoma: Diagnostic performance of 18 F-FDG PET/CT versus conventional imaging for initial staging and follow-up

American Journal of Roentgenology

Volumn 204, Issue 1, 2015, Pages 153-160

  Quartuccio, Natale ^a   Fox, Josef ^b   Kuk, Deborah ^b   Wexler, Leonard H ^b   Baldari, Sergio ^a   Cistaro, Angelina ^c,d,e   Schöder, Heiko ^b  

^a UNIVERSITY OF MESSINA   (Italy)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c Positron Emission Tomography Centre IRMET SpA   (Italy)

^d PET Pediatric AIMN Inter Group   (Italy)

^e INSTITUTE OF COGNITIVE SCIENCES AND TECHNOLOGIES   (Italy)

Author keywords

18F FDG PET CT; Ewing sarcoma; Osteosarcoma; Pediatric bone sarcoma; Prognosis

Indexed keywords

FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ADOLESCENT; ARTICLE; BONE LESION; BONE SCINTISCANNING; CANCER STAGING; CHILD; CHILDHOOD CANCER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; EWING SARCOMA; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; LUNG LESION; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOSARCOMA; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; BONE TUMOR; COMPARATIVE STUDY; DIAGNOSTIC USE; MULTIMODAL IMAGING; OBSERVER VARIATION; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; REPRODUCIBILITY;

ADOLESCENT; BONE NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; MALE; MULTIMODAL IMAGING; NEOPLASM STAGING; OBSERVER VARIATION; OSTEOSARCOMA; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84924929282     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.14.12932     Document Type: Article

References (34)

1. Kaste SC. Imaging pediatric bone sarcomas. Radiol Clin Norih Am 2011 ; 49:749-765
2. Bakhshi S, Radhnkrishnan V. Prognostic markers in osteosarcoma. Expert Rev Anticancer Ther 2010; 10:271-287
3. Treglia G, Salsano M. Stefanelli A, Mattoli MV, Giordano A, Bonomo f.. Diagnostic accuracy of 18F-FDG-PET and PET/CT in patients with Ewing sarcoma family tumours: a systematic review and a meta-analysis. Skeletal Radiol 2012; 41:249-256
4. Wyers MR. Evaluation of pediatric bone lesions. Pediatr Radiol 2010; 40:468-473
5. Esiashvili N, Goodman M, Marcus RB Jr. Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades: surveillance, epidemiology, and end results data.J Pediatr Hematol Oncol 2008; 30:425-430
6. Marina N, Gebhardt M, Teot L, Gorlick R. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 2004; 9:422-441
7. Quartuceio N, Cistaro A. Primary bone tumors. In: Cistara A, ed. Atlas of PET/CT in pediatric patients. Heidelberg, Germany: Springer, 2014
8. Quartuceio N, Treglia G, Salsano M. et al. The role of tluorine-18-fluorodeoxyglucose positron emission tomography in staging and restagingol patients with osteosarcoma./Oncol 2013; 47:97-102
9. Cotterill SJ, Ahrens S, Paulussen M, et al. Prognostie factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergrotip Cooperative Ewing's Sarcoma Study Group. J Clin Oncol 2000; 18:3108-3114
10. Bernstein M, Kovar H, Paulussen M, et al. Ewing's sarcoma family of tumors: current management. Oncologist 2006; 11:503-519
11. Quak E, van de Luijtgaarden AC, de Geus-Oei LF, van der Graaf WT, Oyen WJ. Clinical applications of positron emission tomography in sarcoma management. Expert Rev Anticancer Ther 2011 ; 11:195-204
12. Meyer JS, Nadel HR, Marina N, et al. Imaging guidelines for children with Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group Bone Tumor Committee. Pediatr Blood Cancer 2008; 51:163-170
13. Weiser DA, Kaste SC, Siegel MJ, Adamson PC. Imaging in childhood cancer: A Society for Pediatric Radiology and Children's Oncology group joint task force report. Pediatr Blood Cancer 2013;60:1253-1260
14. Zasadny KR, Wahl RL. Standardized uptake values of normal tissues at PET with 2-[fluorine-l8]-lluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. Radiology 1993; 189:847-850
15. Sugawara Y, Zasadny KR, Neuhoff AW, Wahl RL. Reevaluation of the standardized uptake value for FDG: variations with body weight and methods for correction. Radiology 1999; 213:521-525
16. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J NuclMed2009; 50(suppl 1):I22S-I50S
17. ESMO / European Sarcoma Network Working Group. Bone sarcomas: ESMO Clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23(suppl 7: vi i 100-vii 109
18. Arush MW, Israel O, Postovsky S, et al. Positron emission tomography/computed tomography with I8lluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sarcoma. Pediatr Blood Cancer 2007; 49:901-905
19. Tateishi U, Hosono A, Makimoto A, et al. Accuracy of 18F fluorodeoxyglucose positron emission tomography/computed tomography in staging of pediatric sarcomas. J Pediatr Hematol Oncol 2007; 29:608-612
20. London K, Siege C, Cross S, et al. 18F-FDG PET/CT compared to conventional imaging modalities in pediatric primary bone tumors. Pediatr Radiol 2012;42:418-430
21. Walter F, Czernin J, Hall T, et al. Is there a need for dedicated bone imaging in addition to 18F-FDG PET/CT imaging in pediatric sarcoma patients? J Pediatr Hematol Oncol 2012; 34:131-136
22. lagaru A, Chawla S, Mencndez L, Conti PS. 18F-FDG PET and PET/CT for detection of pulmonary metastases from musculoskeletal sarcomas. Nucl Med Commun 2006; 27:795-802
23. Kleis M, Daldrup-Link H, Matthay K, et al. Diagnostic value of PET/CT for the staging and restag-ing of pediatric tumors. Eur J Nucl Med Mol Imaging 2009;36:23-36
24. Fuglø HM, Jørgensen SM, Loft A, Hovgaard D, Petersen MM. The diagnostic and prognostic value of F.18F-FDG PET/CT in the initial assessment of high-grade bone and soft tissue sarcoma: a retrospective study of 89 patients. Eur J Nucl Med Mol Imaging 2012; 39:1416-1424
25. Cistaro A, Lopci E, Gastaldo L, fania P, Brach Del Prever A. Fagioli F. The role of 18F-FDG PET/CT in the metabolic characterization of lung nodules in pediatric patients with bone sarcoma. Pediatr Blood Cancer 2012; 59:1206-1210
26. Maki RG. Pediatric sarcomas occurring in adults. J Surg Oncol 2008; 97:360-368
27. Ulaner GA, Magnati H, Healey JH, Weber WA, Meyers PA. Is methylene diphosphonate bone scan necessary for initial staging of Ewing sarcoma if FDG PET/CT is performed? AJR 2014; 202:859-867
28. Benz MR, Czernin J, Tap WD, let al. FDG-PET/CT imaging predicts histopathologic treatment responses after neoadjuvant therapy in adult primary bone sarcomas. Sarcoma 2010; 2010:143540
29. Byun BH, Hong CB, Lim I, et al.. Early response monitoring to neoadjuvant chemotherapy in osteosarcoma using sequential 18F-FDG PET/CT and MR1. Eur J Nucl Med Mol Imaging 2014; 41:1553-1562
30. Kager L, Zoubek A, Pötschger U, et al; Cooperative German-Austrian-Swiss Osteosarcoma Study Group. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 2003; 21:2011-2018
31. Piperkova E, Mikhaeil M, Mousavi A, et al. Impact of PET and CT in PET/CT studies for staging and evaluating treatment response in bone and soft tissue sarcomas. Clin Nucl Med 2009; 34:146-150
32. Huda W, Vance A. Patient radiation doses from adult and pediatric CT. AJR 2007; 188:540-546
33. Fahey FH. Dosimetry of pediatric PET/CT. J Nucl Med 2009; 50:1483-1491
34. Buchbender C, Heusner TA, Lauenstein TC, Bockisch A, Antoch G. Oncologic PET/MRI. Part 2. Bone tumors, soft-tissue tumors, melanoma, and lymphoma. J Nucl Afe/2012; 53:1244-1252